OPKO Health, Inc. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
OPKO Health, Inc. (OPK) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $2.35 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2016-11-07
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2016-09-30 was $3.25M.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2016-06-30 was -$6.32M.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2016-03-31 was $5.43M.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-12-31 was -$8.85M.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2015 was -$17.45M.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2014 was -$16.13M, a 2612.77% decline from fiscal 2013.
- OPKO Health, Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2013 was $642.00K.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2016-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$3.08M derived: sum of 2 quarters · filed 2016-11-07 | $2.35M 10-Q · filed 2016-11-07 | -$6.50M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | -$6.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$894.00K 10-Q · filed 2016-08-08 | -$9.75M derived: sum of 3 quarters · filed 2016-08-08 | -$11.86M derived: sum of 4 quarters · filed 2016-08-08 |
| 2016-03-31 | $5.43M 10-Q · filed 2016-05-09 | -$3.42M derived: sum of 2 quarters · filed 2016-05-09 | -$5.54M derived: sum of 3 quarters · filed 2016-05-09 | -$6.91M derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | -$8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$10.96M derived: sum of 2 quarters · filed 2016-02-29 | -$12.34M derived: sum of 3 quarters · filed 2016-02-29 | -$17.45M 10-K · filed 2016-02-29 |
| 2015-09-30 | -$2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$3.49M derived: sum of 2 quarters · filed 2015-11-09 | -$8.60M 10-Q · filed 2015-11-09 | -$13.17M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$6.49M 10-Q · filed 2015-08-05 | -$11.06M derived: sum of 3 quarters · filed 2016-02-29 | -$20.06M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-03-31 | -$5.11M 10-Q · filed 2015-05-11 | -$9.68M derived: sum of 2 quarters · filed 2016-02-29 | -$18.68M derived: sum of 3 quarters · filed 2016-02-29 | -$19.78M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-12-31 | -$4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$13.57M derived: sum of 2 quarters · filed 2016-02-29 | -$14.67M derived: sum of 3 quarters · filed 2016-02-29 | -$16.13M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$10.10M derived: sum of 2 quarters · filed 2014-11-07 | -$11.56M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$2.56M 10-Q · filed 2014-08-11 | ||
| 2014-03-31 | -$1.47M 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $642.00K 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |